Daiichi Sankyo Company Profile
✉ Email this page to a colleague
What is the competitive landscape for DAIICHI SANKYO, and what generic alternatives to DAIICHI SANKYO drugs are available?
DAIICHI SANKYO has three approved drugs.
There are twenty-five US patents protecting DAIICHI SANKYO drugs.
There are three hundred and twenty-three patent family members on DAIICHI SANKYO drugs in forty-five countries and twenty supplementary protection certificates in fifteen countries.
Summary for Daiichi Sankyo
International Patents: | 323 |
US Patents: | 25 |
Tradenames: | 3 |
Ingredients: | 3 |
NDAs: | 3 |
PTAB Cases with Daiichi Sankyo as patent owner: | See PTAB cases with Daiichi Sankyo as patent owner |
Drugs and US Patents for Daiichi Sankyo
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Daiichi Sankyo Inc | TURALIO | pexidartinib hydrochloride | CAPSULE;ORAL | 211810-002 | Oct 14, 2022 | RX | Yes | No | 10,941,142 | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Daiichi Sankyo Inc | VANFLYTA | quizartinib dihydrochloride | TABLET;ORAL | 216993-002 | Jul 20, 2023 | RX | Yes | Yes | 9,585,892 | ⤷ Sign Up | ⤷ Sign Up | ||||
Daiichi Sankyo Inc | TURALIO | pexidartinib hydrochloride | CAPSULE;ORAL | 211810-002 | Oct 14, 2022 | RX | Yes | No | 7,893,075 | ⤷ Sign Up | Y | ⤷ Sign Up | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Paragraph IV (Patent) Challenges for DAIICHI SANKYO drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Tablets | 15 mg, 30 mg and 60 mg | ➤ Subscribe | 2019-01-28 |
International Patents for Daiichi Sankyo Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Cyprus | 1114099 | ⤷ Sign Up |
World Intellectual Property Organization (WIPO) | 2010132787 | ⤷ Sign Up |
Norway | 2024011 | ⤷ Sign Up |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Daiichi Sankyo Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
2140867 | PA2018005 | Lithuania | ⤷ Sign Up | PRODUCT NAME: EDOKSABANAS, JO FARMACINIU POZIURIU PRIIMTINA DRUSKA, ARBA BET KURIO IS JU HIDRATAS, YPAC EDOKSABANO P-TOLUENSULFONATO MONOHIDRATAS; REGISTRATION NO/DATE: EU/1/15/993/001-028 20150619 |
1405852 | 2015/045 | Ireland | ⤷ Sign Up | PRODUCT NAME: EDOXABAN, A SALT THEREOF, A SOLVATIC THEREOF, OR AN N-OXIDE THEREOF, IN PARTICULAR EDOXABAN TOSYLATE; REGISTRATION NO/DATE: EU/1/15/993/001-028 20150619 |
1405852 | 122015000077 | Germany | ⤷ Sign Up | PRODUCT NAME: EDOXABAN, DESSEN SALZ, DESSEN SOLVAT, ODER DESSEN N-OXID, INSBESONDERE EDOXABANTOSILAT; REGISTRATION NO/DATE: EU/1/15/993/001-028 20150619 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.